Compounds, compositions and methods

Patent metadata

Field	Value
Publication number	US-9896458-B2
Application number	US-201715721419-A
Country	US
Kind code	B2
Filing date	Sep 29, 2017
Priority date	Feb 5, 2016
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

First claim

The invention claimed is:

1. A compound having the structure:

or a pharmaceutically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof, and a pharmaceutically acceptable excipient.

3. A compound having the structure:

4. A pharmaceutical composition comprising the compound of claim 3 , and a pharmaceutically acceptable excipient.

5. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising the compound of claim 5 , and a pharmaceutically acceptable excipient.

Assignees

• Denali Therapeutics Inc

Inventors

• Estrada Anthony A
• Feng Jianwen A
• Fox Brian
• Sweeney Zachary K

Classifications

• A61P9/02

  Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title